酸盐结合剂与慢性血液透析患者便秘之间的关联:一个横截面研究
Mayuko Hori1, Hiroshi Takahashi2, Chika Kondo1
1Department of Nephrology, Masuko Memorial Hospital, Japan.
Internal medicine (Tokyo, Japan)
|December 17, 2025
概括
在血液透析患者中,便秘很常见. 特定的酸盐结合剂,如碳酸和沉碳酸,可能会降低便秘的风险,这表明在患者管理中发挥了作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 便秘和肠道失调在血液透析患者中很常见,与尿血和诸如心血管疾病等不良结果有关.
- 用于末期病的酸结合剂可能会影响肠道微生物群和超出酸控制的全身健康.
- 关于酸盐结合剂在该人群中对便秘的特定影响的临床证据有限.
研究的目的:
- 研究在接受血液透析的患者中使用酸盐结合剂和便秘之间的关联.
- 为了确定特定的酸盐结合剂,可以减轻这种患者群体中便秘的风险.
主要方法:
- 在日本马苏科纪念医院对293名血液透析门诊患者进行的横截面研究.
- 收集关于患者特征和药物使用的数据.
- 使用包括罗马IV和药史在内的原始标准评估便秘.
主要成果:
- 超过一半的参与者 (51.9%) 患有便秘,20.5% 患有严重便秘.
- 兰碳酸盐的使用独立地与便秘和严重便秘的风险较低有关.
- 沉碳酸盐的急性使用独立地与较低的严重便秘风险有关.
结论:
- 特定的酸盐结合剂,即碳酸和沉碳酸,与血液透析患者便秘的风险降低有关.
- 酸盐结合剂的选择可能会考虑它们对便秘的有益影响,可能会改善患者的治疗结果.
相关概念视频
Peritoneal Dialysis III: Nursing Management
592
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
592
Chronic Kidney Disease III: Interprofessional Care
320
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
320
Hemodialysis III: Nursing Management
687
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
687
Chronic Kidney Disease II: Clinical Manifestations
522
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
522
Hemodialysis II: Procedure and Complications
567
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
567
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
476
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
476


